CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows used in operating activities:
Net loss	$ (15,775,572)	$ (13,587,748)
Adjustments to reconcile net loss to net cash from operating activities
Depreciation	209,076	306,965
Amortization of intangibles and interest accretion of contingent consideration	3,950,550	3,794,735
Amortization of deferred financing costs	777,324	947,818
Accretion of notes receivable	(171,046)
Deferred income tax benefit	(5,999,000)	(2,810,000)
Gain on sale of investment		(3,605,263)
Loss on disposal of equipment	152,720	4,880
Loss on sale of PML	215,401
Stock-based compensation expense	2,518,970	1,024,835
Expense from stock options issued in exchange for services	119,134	294,796
Cancellation of ParaPRO stock options in connection with termination of contract	(1,293,720)
Change in fair value of put right		3,970,789
Change in fair value of contingent consideration		(283,000)
Impairment charge	6,456,966
Changes in operating assets and liabilities (net of effect of acquisitions and dispositions):
Accounts receivable	2,924,303	11,164,747
Inventory	695,703	4,136,232
Prepaid expenses and other assets	35,970	(915,804)
Accounts payable	4,388,557	5,803,724
Income taxes	(4,029,690)	(3,545,938)
Accrued expenses	(5,371,000)	(7,234,683)
Net cash used in operating activities	(10,195,354)	(532,915)
Cash flows provided by investing activities:
Proceeds from sale of investment		4,605,263
Acquisition of Cypress		(309,589)
Proceeds from the sale of PML	1,177,665
Proceeds from sale of property and equipment	40,800	23,000
Purchase of equipment	(419,430)	(278,965)
Net cash provided by investing activities	799,035	4,039,709
Cash flows provided by (used in) financing activities:
Cash acquired in connection with acquisition of Somaxon		2,880,837
Payments on original Midcap Loan		(12,497,196)
Payments on Midcap term loan		(2,299,802)
Proceeds from issuance of convertible senior notes	65,000,000
Payment on financing costs	(6,230,699)
Net payments on Midcap revolving credit facility	(3,730,994)	(3,842,193)
Payment on contracts payable	(1,500,000)	(1,533,334)
Payments on mortgages and capital leases	(46,420)	(81,210)
Income tax benefit on stock-based awards	(147,000)	(84,000)
Proceeds from exercise of stock options	1,948,870	184,015
Payment of employee income tax liability with surrender of employee restricted stock	(752,925)	(208,613)
Net cash provided by (used in) financing activities	54,540,832	(17,481,496)
Net increase (decrease) in cash and cash equivalents	45,144,513	(13,974,702)
Cash and cash equivalents, beginning of period	15,646,963	23,022,821
Cash and cash equivalents, end of period	60,791,476	9,048,119
Supplemental Disclosure:
Cash paid for income taxes	560,691	1,320,939
Interest paid during the period	2,617,157	2,001,022
Non-cash transactions
Accrued bonus paid in restricted common stock		46,022
Acquisition of license - contract payable	2,500,000	500,000
Acquisition of Cypress and Somaxon - purchase price adjustment		4,736,250
Acquisition of Somaxon - fair value of common stock		$ 23,840,424